Drug
Zilebesiran
Zilebesiran: highest development phase Phase 3, developed by Alnylam Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Zilebesiran NCT07181109 | Phase 3 | High Risk Cardiovascular Disease |
| Zilebesiran NCT06423352 | Phase 1/2 | Mild to Moderate Hypertension |
Latest
Follow Zilebesiran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.